Positive outcome no more likely in industry-funded trials

Positive outcome no more likely in industry-funded trials
Industry-sponsored clinical trials of rheumatoid arthritis drugs are no more likely to report positive outcomes than trials funded by other means, and in many cases use better methodology, according to research published in the July issue of Arthritis & Rheumatism.

(HealthDay) -- Industry-sponsored clinical trials of rheumatoid arthritis drugs are no more likely to report positive outcomes than trials funded by other means, and in many cases use better methodology, according to research published in the July issue of Arthritis & Rheumatism.

Nasim A. Khan, M.D., from the University of Arkansas for Medical Sciences in Little Rock, and colleagues reviewed 103 randomized controlled trials (RCTs) for rheumatoid drugs to examine whether industry funding was associated with outcomes.

The researchers found that 56.3 percent of RCTs were funded by industry, 18.4 percent were funded through nonprofit sources, 5.8 percent had mixed funding, and the funding source was not specified in the remaining 19.4 percent. In the 86 trials examined for outcomes there was no correlation between industry funding and positive outcomes (75.5 percent for industry versus 68.8 percent for non-industry, 40 percent for mixed, and 81.2 percent for unspecified). Industry-funded studies were more likely not to be published (P = 0.093) but were more likely to be double-blinded, adequately describe participant flow, and perform an intent-to-treat analysis.

"Industry funding was not associated with a higher likelihood of positive outcomes of published RCTs of drug therapy for , and industry-funded RCTs performed significantly better than non-industry-funded RCTs in terms of reporting the use of some key methodologic quality measures," Khan and colleagues conclude.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Cartilage actively contributes to arthritis

Sep 12, 2014

Melbourne researchers have discovered that cartilage plays an active role in the destruction and remodelling of joints seen in rheumatoid arthritis, rather than being an 'innocent bystander' as previously ...

Blocking one receptor could halt rheumatoid arthritis

Sep 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and ...

Motion analysis to detect arthrosis

Sep 04, 2014

Arthrosis  is excessive wear of joints beyond the usual age-related degeneration. For this reason, about 150,000 Germans are provided with an artificial knee joint every year. Early diagnosis and corresponding ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Gys
not rated yet Jul 06, 2012
I just downloaded the full text of this article and there is no statement about the conflict of interest for the authors. Which makes me laugh.